By Colin Kellaher


Nuvectis Pharma Inc. on Thursday said the U.S. Food and Drug Administration granted fast-track designation to its NXP800 drug candidate in a form of ovarian cancer.

The Fort Lee, N.J., biopharmaceutical company said the designation covers NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 01, 2022 08:30 ET (13:30 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.